BioSpace News Archive

Sigilon Therapeutics announced it may have discovered the reason why its experimental cell therapy treatment for severe hemophilia A was placed on clinical hold by the FDA.

Two biopharma companies developing therapeutics in the oncology space begin the week with strong signals in Phase II.

Are you looking for doctor careers in the pharma sector? Here is everything you need to know about how you can choose a reputable and growing pharma career.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced new long-term durability data from the Phase 1/2 studies of DTX401 for Glycogen Storage Disease Type Ia (GSDIa) and DTX301 for Ornithine Transcarbamylase (OTC) deficiency that were presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM).

Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.

Ceapro Inc. announced they are receiving advisory services and up to $480,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to support Ceapro’s project entitled, “Boosting innovation capacity of Pressurized Gas eXpanded Technology towards pharmaceutical applications.”

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the FDA has informed the Company that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee is tentatively scheduled for February 15, 2022.

Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop®, today announced the FDA 510(k) clearance and launch of its new advanced image reconstruction technology using deep learning (DL).

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company’s suite of COVID-19 PCR diagnostic assays.

Remedium Bio, Inc., is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development.